Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection

Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients... Downloaded from http://journals.lww.com/aidsonline by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection a b a Gema M. Lledo  , Itziar Carrasco , Laura M. Benı´tez-Gutierrez , a c b Ana Arias , Ana Royuela , Silvia Requena , a b Valentı´n Cuervas-Mons and Carmen de Mendoza Background: Treatment with direct-acting antivirals (DAA) eradicates hepatitis C virus (HCV) from most chronic carriers. Information on regression of liver fibrosis and the influence of HIV is scarce in cured patients. Methods: All consecutive HCV-infected individuals treated with DAA at our institution were examined. Hepatic elastography was performed at baseline and at the time of SVR12. Liver fibrosis regression was defined as a shift from advanced fibrosis (Metavir F3-F4) to null–mild fibrosis (F0–F2) and/or a reduction greater than 30% kPa. AST to platelet ratio index (APRI) and fibrosis 4 (FIB-4) scores were calculated in parallel. Results: A total of 260 patients were treated with DAA. All but 14 achieved SVR12 and represented the study population. HIV confection was present in 42%. At baseline, 57.2% had advanced liver fibrosis with a median of 11 kPa, FIB-4 of 2.4, and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Wolters Kluwer Health

Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection

Loading next page...
 
/lp/wolters-kluwer-health/regression-of-liver-fibrosis-after-curing-chronic-hepatitis-c-with-OpWys7keV7

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
0269-9370
eISSN
1473-5571
DOI
10.1097/QAD.0000000000001966
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/aidsonline by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection a b a Gema M. Lledo  , Itziar Carrasco , Laura M. Benı´tez-Gutierrez , a c b Ana Arias , Ana Royuela , Silvia Requena , a b Valentı´n Cuervas-Mons and Carmen de Mendoza Background: Treatment with direct-acting antivirals (DAA) eradicates hepatitis C virus (HCV) from most chronic carriers. Information on regression of liver fibrosis and the influence of HIV is scarce in cured patients. Methods: All consecutive HCV-infected individuals treated with DAA at our institution were examined. Hepatic elastography was performed at baseline and at the time of SVR12. Liver fibrosis regression was defined as a shift from advanced fibrosis (Metavir F3-F4) to null–mild fibrosis (F0–F2) and/or a reduction greater than 30% kPa. AST to platelet ratio index (APRI) and fibrosis 4 (FIB-4) scores were calculated in parallel. Results: A total of 260 patients were treated with DAA. All but 14 achieved SVR12 and represented the study population. HIV confection was present in 42%. At baseline, 57.2% had advanced liver fibrosis with a median of 11 kPa, FIB-4 of 2.4, and

Journal

AIDSWolters Kluwer Health

Published: Oct 1, 2018

There are no references for this article.